HC Wainwright Reiterates "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS)

HC Wainwright reiterated their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS - Free Report) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock.

Separately, Piper Sandler restated an "overweight" rating and set a $7.00 price target on shares of Alpha Tau Medical in a research report on Thursday, August 15th.

Alpha Tau Medical Price Performance

DRTS stock traded up $0.04 during mid-day trading on Wednesday, reaching $2.25. 7,136 shares of the company's stock were exchanged, compared to its average volume of 31,912. The company has a market cap of $156.76 million, a price-to-earnings ratio of -5.39 and a beta of 0.77. Alpha Tau Medical has a 12-month low of $1.75 and a 12-month high of $3.65. The stock's 50 day moving average is $2.28 and its 200 day moving average is $2.35. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.66 and a quick ratio of 11.60.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. On average, research analysts expect that Alpha Tau Medical will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of large investors have recently modified their holdings of the business. USAdvisors Wealth Management LLC acquired a new position in Alpha Tau Medical during the first quarter worth about $30,000. Aptus Capital Advisors LLC grew its position in shares of Alpha Tau Medical by 83.7% in the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company's stock valued at $56,000 after purchasing an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. increased its holdings in shares of Alpha Tau Medical by 83.7% in the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company's stock valued at $56,000 after purchasing an additional 10,000 shares during the last quarter. Caprock Group LLC acquired a new stake in shares of Alpha Tau Medical in the second quarter valued at approximately $59,000. Finally, Levin Capital Strategies L.P. lifted its position in Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company's stock worth $999,000 after buying an additional 8,641 shares in the last quarter. Hedge funds and other institutional investors own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.